Skip to main content

2013 | OriginalPaper | Buchkapitel

24. Pharmakotherapie von Gedächtnisstörungen

verfasst von : G. Gründer

Erschienen in: Gedächtnisstörungen

Verlag: Springer Berlin Heidelberg

Zusammenfassung

Die Pharmakotherapie von Gedächtnisstörungen kann prinzipiell nicht isoliert von einer umfassenderen Therapie von kognitiven Störungen betrachtet werden. Vor diesem Hintergrund werden in diesem Kapitel Arzneimittel besprochen, die für die Behandlung von Erkrankungen zugelassen sind, bei denen Gedächtnisstörungen einen zentralen Bestandteil der Pathologie repräsentieren (z. B. Acetylcholinesterase-Inhibitoren bei Demenz vom Alzheimer-Typ), oder für die aus klinischen Studien eine gewisse Evidenz für eine Wirksamkeit gegen kognitive Störungen besteht, die aber in dieser Indikation nicht – wohl aber für die Behandlung anderer Erkrankungen – zugelassen sind (z. B. Modafinil bei kognitiven Störungen im Rahmen schizophrener Störungen). Eine dritte Gruppe umfasst experimentelle Substanzen, denen bisher eine Zulassung in jeglicher Indikation fehlt, die sich also noch in der klinischen Prüfung befinden.
Literatur
Zurück zum Zitat Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O’Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378:403–411 PubMedCrossRef Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Knapp M, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O’Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A (2011) Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 378:403–411 PubMedCrossRef
Zurück zum Zitat Benkert O, Hippius H (2012) Kompendium der Psychiatrischen Pharmakotherapie, 9. Aufl. Springer, Berlin Heidelberg New York Benkert O, Hippius H (2012) Kompendium der Psychiatrischen Pharmakotherapie, 9. Aufl. Springer, Berlin Heidelberg New York
Zurück zum Zitat Dobkin RD, Menza M, Bienfait KL, Gara M, Marin H, Mark MH, Dicke A, Tröster A (2010) The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 22:188–195 PubMedCentralPubMedCrossRef Dobkin RD, Menza M, Bienfait KL, Gara M, Marin H, Mark MH, Dicke A, Tröster A (2010) The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 22:188–195 PubMedCentralPubMedCrossRef
Zurück zum Zitat Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 369:208–216 PubMedCrossRef Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 369:208–216 PubMedCrossRef
Zurück zum Zitat Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ (2012) COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol Psychiatry 71:538–544 PubMedCentralPubMedCrossRef Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ (2012) COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol Psychiatry 71:538–544 PubMedCentralPubMedCrossRef
Zurück zum Zitat Fleischhacker WW, Hofer A (2012) Schizophrene Störungen. In: Gründer G, Benkert O (Hrsg.) Handbuch der Psychopharmakotherapie, 2. Aufl. Springer, Berlin, Heidelberg New York Fleischhacker WW, Hofer A (2012) Schizophrene Störungen. In: Gründer G, Benkert O (Hrsg.) Handbuch der Psychopharmakotherapie, 2. Aufl. Springer, Berlin, Heidelberg New York
Zurück zum Zitat Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 198:351–356 PubMedCrossRef Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 198:351–356 PubMedCrossRef
Zurück zum Zitat Frakey LL, Salloway S, Buelow M, Malloy P (2012) A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer’s disease. J Clin Psychiatry 73:796–801 PubMedCrossRef Frakey LL, Salloway S, Buelow M, Malloy P (2012) A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer’s disease. J Clin Psychiatry 73:796–801 PubMedCrossRef
Zurück zum Zitat Gründer G, Benkert O (Hrsg.) (2012) Handbuch der Psychopharmakotherapie, 2. Aufl. Springer, Berlin, Heidelberg New York CrossRef Gründer G, Benkert O (Hrsg.) (2012) Handbuch der Psychopharmakotherapie, 2. Aufl. Springer, Berlin, Heidelberg New York CrossRef
Zurück zum Zitat Gründer G (2012) Cognitive Enhancers. In: Gründer G, Benkert O (Hrsg.) Handbuch der Psychopharmakotherapie, 2. Aufl. Springer, Berlin, Heidelberg New York CrossRef Gründer G (2012) Cognitive Enhancers. In: Gründer G, Benkert O (Hrsg.) Handbuch der Psychopharmakotherapie, 2. Aufl. Springer, Berlin, Heidelberg New York CrossRef
Zurück zum Zitat Jorge RE, Acion L, Moser D, Adams HP Jr, Robinson RG (2010) Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 67:187–196 PubMedCentralPubMedCrossRef Jorge RE, Acion L, Moser D, Adams HP Jr, Robinson RG (2010) Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 67:187–196 PubMedCentralPubMedCrossRef
Zurück zum Zitat Kane JM, D’Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J Clin Psychiatry 71:1475–1481 Kane JM, D’Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J Clin Psychiatry 71:1475–1481
Zurück zum Zitat Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators; Neurocognitive Working Group (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633–647 PubMedCrossRef Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators; Neurocognitive Working Group (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633–647 PubMedCrossRef
Zurück zum Zitat Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, Nelson M, Gold JM, Ball MP, Feldman S, Liu F, Conley RR (2009) A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry 70:518–525 PubMedCrossRef Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D, Nelson M, Gold JM, Ball MP, Feldman S, Liu F, Conley RR (2009) A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry 70:518–525 PubMedCrossRef
Zurück zum Zitat Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A; MEM-MD-29 Study Group (2009) A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34:1322–1329 Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, Gage A; MEM-MD-29 Study Group (2009) A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 34:1322–1329
Zurück zum Zitat Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL; Alzheimer’s Disease Cooperative Study Group (2009) Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 72:2115–2121 CrossRef Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL; Alzheimer’s Disease Cooperative Study Group (2009) Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 72:2115–2121 CrossRef
Zurück zum Zitat McKinzie DL, Bymaster FP (2012) Muscarinic mechanisms in psychotic disorders. Handb Exp Pharmacol 213:233–265 PubMedCrossRef McKinzie DL, Bymaster FP (2012) Muscarinic mechanisms in psychotic disorders. Handb Exp Pharmacol 213:233–265 PubMedCrossRef
Zurück zum Zitat Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG; Depression in Alzheimer’s Disease Study–2 Research Group (2012) Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry 20:1036–1044 PubMedCentralPubMedCrossRef Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG; Depression in Alzheimer’s Disease Study–2 Research Group (2012) Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry 20:1036–1044 PubMedCentralPubMedCrossRef
Zurück zum Zitat Raschetti R, Albanese E, Vanacore N, Maggini M (2007) Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4:e338 PubMedCentralPubMedCrossRef Raschetti R, Albanese E, Vanacore N, Maggini M (2007) Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4:e338 PubMedCentralPubMedCrossRef
Zurück zum Zitat Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC (2007) Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164:900–909 PubMedCrossRef Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC (2007) Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 164:900–909 PubMedCrossRef
Zurück zum Zitat Reynolds CF 3rd, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, Lenze EJ, Holm M, Rogers JC, Mazumdar S, Houck PR, Begley A, Anderson S, Karp JF, Miller MD, Whyte EM, Stack J, Gildengers A, Szanto K, Bensasi S, Kaufer DI, Kamboh MI, DeKosky ST. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 68:51–60 Reynolds CF 3rd, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, Lenze EJ, Holm M, Rogers JC, Mazumdar S, Houck PR, Begley A, Anderson S, Karp JF, Miller MD, Whyte EM, Stack J, Gildengers A, Szanto K, Bensasi S, Kaufer DI, Kamboh MI, DeKosky ST. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 68:51–60
Zurück zum Zitat Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM (2010) Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs 24:303–317 PubMedCrossRef Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM (2010) Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs 24:303–317 PubMedCrossRef
Zurück zum Zitat Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, McMahon RP, Kelly DL (2012) Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37:660–668 PubMedCentralPubMedCrossRef Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, McMahon RP, Kelly DL (2012) Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37:660–668 PubMedCentralPubMedCrossRef
Zurück zum Zitat S3-Leitlinie „Demenzen“ (2009) Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Neurologie (DGN) S3-Leitlinie „Demenzen“ (2009) Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Neurologie (DGN)
Zurück zum Zitat Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG (2011) Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav 99:130–145 PubMedCrossRef Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG (2011) Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav 99:130–145 PubMedCrossRef
Zurück zum Zitat Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Nazem S, Ten Have TR, Stern MB (2010) Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75:448–455 PubMedCentralPubMedCrossRef Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Nazem S, Ten Have TR, Stern MB (2010) Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75:448–455 PubMedCentralPubMedCrossRef
Metadaten
Titel
Pharmakotherapie von Gedächtnisstörungen
verfasst von
G. Gründer
Copyright-Jahr
2013
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-642-36993-3_24